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Patients First Health Plan
Formulary Drug Monograph

Generic Name:

dupilumab

Brand Name:

DUPIXENT®

Manufacturer:

Regeneron Pharmaceuticals, Inc./sanofi-aventis U.S. LLC

Date of Review:

January 27, 2020

Purpose:

FDA approved; consider new indication

Indication:

Add-on maintenance treatment in patients with
moderate-to-severe asthma aged 12 years and older with an
eosinophilic phenotype or with oral corticosteroid dependent
asthma

Therapeutic Alternatives
AGENTS IN THE SAME PHARMACOLOGIC CLASS
Preferred/Formulary

Nonpreferred/Nonformulary
FasenraⓇ
NucalaⓇ
XolairⓇ

AGENTS IN A DIFFERENT PHARMACOLOGIC CLASS
Preferred/Formulary

Nonpreferred/Nonformulary

Fluticasone

Albuterol sulfate

Montelukast

Beclomethasone dipropionate

Salmeterol

Mometasone furoate
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Abbreviations used in this monograph:
ACQ

Asthma control questionnaire

IL

Interleukin

ACQ-5

Five question asthma control questionnaire

LABA

Long-acting beta 2 agonist

AE

Adverse event

MCID

Minimal clinically important difference

AWP

Average wholesale price

NNT

Number needed to treat

CBC

Complete blood count

OCS

Oral corticosteroid

CDC

Centers for Disease Control

PMPM

Per member per month

CEPAC

Comparative Effectiveness Public Advisory Council

QALY

Quality-adjusted life-year

FeNO

Fraction exhaled nitric oxide

q2w

Every two weeks

FEV1

Forced expiratory volume in 1 second

SOC

Standard of care

ICER

Institute for Clinical and Economic Review

SUBQ

Subcutaneous injection

IgE

Immunoglobulin E

US

United States
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Executive Summary

Efficacy in Clinical Trials (Strength of Evidence: Medium)
DupixentⓇ decreased the risk of an asthma related exacerbation in the overall population treated when
compared to the placebo group in treatment. DupixentⓇ also increased the FEV1 value in the overall treated
population when compared to the placebo group. The improvements of the FEV1 were seen within 2 weeks,
but then were still apparent over 52 weeks after the last treatment.1 Studies typically focus on the number of
exacerbations and FEV1 values for considering the efficacy of DupixentⓇ in the target patient subgroups. In
comparison to the current treatments available, including inhaled corticosteroids and LABAs, DupixentⓇ
provides greater efficacy in the treatment of moderate-to-severe asthma, increasing quality of life and patient
outcomes.1

Reason for evidence grade: DupixentⓇ trials were powered for number of exacerbations and the FEV1 values
of DupixentⓇ treatment group when compared to the placebo group. However, while in the trials, patients
were still using inhaled corticosteroids and LABAs, which could alter the results of the treatment when
compared to the placebo.1

Safety in Clinical Trials  (Strength of Evidence: Low)
Studies report minimal discontinuation of DupixentⓇ due to adverse effects. Common adverse events
experienced were upper respiratory tract infections and injection site reactions. Other less common adverse
events consisted of headache, nasopharyngitis, and bronchitis.1
Reason for evidence grade: Since DupixentⓇ was recently approved, no long-term safety data exists.
Additionally, no information is present on the use of DupixentⓇ in pregnant women. Minimal safety data has
been identified, however extensive powered safety trials have not been completed. In safety trials, the trials
are not powered due to small numbers. Post-marketing safety data from phase IV trials will be of more
value.1

Real World Comparative Effectiveness  (Strength of Evidence: Low)
No comparative or effectiveness evidence is published for DupixentⓇ for asthma, however real world
evidence for atopic dermatitis has been established.
Reason for evidence grade: No comparative or effectiveness evidence exists for DupixentⓇ for Asthma.

Value Proposition  (Strength of Evidence: High)
Based on the CDC-reported asthma prevalence in 2016 and the prevalence of persistent asthma, Patients First
Health will supply a maximum of about 43,000 patients falling under the DupixentⓇ indication for asthma.
With the introduction of DupixentⓇ among this patient subgroup, the projected decrease in PMPM in year 1
is $0.0017 and up to $0.0175 in year 5.1 The maximum cost savings of introducing DupixentⓇ in our
calculated patient prevalence would be $72.96 in year one and about $751.09 in year 5. According to data
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from the Institute of Clinical and Economic Review, the US exacerbation cost resulting in emergency
department visits, hospitalization, and steroid therapy was averaged to $12,634 per patient.2 Results for the
Liberty Asthma Quest study found that DupixentⓇ reduced the probability of asthma exacerbations by about
50% when compared with placebo (RR of 0.523 for the 200mg dose). The NNT in order to meet this
reduction was 2.1 The study found that DupixentⓇ use was able to reduce exacerbation related hospitalization
in half as well, with a NNT of 34. We calculated that DupixentⓇ therapy can therefore reduce Patients First
Health’s medical plan costs related to exacerbations resulting in hospitalization by about $16 million per
year, assuming all eligible patients were treated and had 2 annual exacerbations. In the Liberty Asthma
Venture trial, DupixentⓇ was found to decrease OCS dose to less than 5 mg/day in 70% of treated patients
compared to one third of placebo. NNT calculated to reach this was 3. Almost 50% of DupixentⓇ treated
patients even completely eliminated OCS use by the end of the study.1 The annual cost for the long term use
of OCS, including treatment of AE’s was $7,983.2 DupixentⓇ can decrease the cost of prescription drug
treatment with steroids and medical costs of treating any adverse effects resulting from OCS use.
Additionally, DupixentⓇ is the only biologic that is used only by self-administration. XolairⓇ and CinqairⓇ
are required in office administration and FasenraⓇ and NucalaⓇ have the in office option.3,4,5,6,7 The averaged
in office based physician charge for administration was $74.16, not including the cost of the drug. CinqairⓇ
is an IV therapy, so would have a higher cost of $144.72. DupixentⓇ would eliminate in office charges and
would only require the plan to cover the prescription drug cost. We concluded that there would be no
additional monitoring price per patient for DupixentⓇ therapy. Blood eosinophil count would be the major
monitoring parameter needed, but patients with the indication will be required to monitor their asthma with
routine parameter including testing a CBC regardless of DupixentⓇ treatment. Further economic evaluations
should be studied to simulate more real-world treatment scenarios.
Target Patient Subgroups (Strength of Evidence: Medium)
Patients enrolled in the Liberty Asthma Quest study were required to be at least 12 years old with a diagnosis
of asthma for more than one year, who were currently being treated with a medium to high dose ICS and 1 or
2 controller treatments for over three months and 1 month of consistent dosing. Patients ACQ-5 scores were
greater than 1.5 at baseline and had worsening asthma, resulting in hospitalization or treatment with a
systemic corticosteroid within the past year, but no earlier than 1 month before baseline visit. Excluded
patients included those with other lung diseases, obesity, and current or past smokers.1 Studies found that
patients with a blood eosinophil count of greater than 300 cells/μL resulted in better outcomes than patients
lower eosinophil levels. Other subgroups that showed better outcomes include patients with at least two
exacerbations in the past year, those with an ACQ-5 score greater than or equal to 1.5, and chronic OCS
users.2 Not all studies were powered for these subgroups, but they were found to be more cost-effective due
to having a higher probability of better outcomes than other subgroups. Post-marketing studies of DupixentⓇ
use in the indicated asthma patients should be evaluated to find significant evidence towards treating these
specific patients.

Evidence Gaps

Population
The mean age in the Liberty Asthma Quest and Liberty Asthma Venture trials was around 50 years old, with
about 40% of patients being male.1 The clinical trials studying DupixentⓇ in moderate to severe asthma
patients have good external validity of Patients First Health Plan membership. The majority of covered
5

patients in this health plan fell in the 18-64 year old range and were evenly distributed among gender. We
find no relevant evidence gap of the population studied in clinical trials for DupixentⓇ. Patients First Health
Plan also mostly covers patients aged 12 years and older, the indicated age for DupixentⓇ use, with only 16%
of patients being below 12. The use of competitor, XolairⓇ, in pediatric patients aged 6 and up is not as
clinically relevant to the patient demographic in our membership.

Intervention
The self administration of subcutaneous injections could potentially decrease compliance for patients who
have a fear of needles. With the DupixentⓇ prefilled syringe, patients are able to see the needle, unlike auto
injection devices, increasing the likelihood that patients with a fear of injections will not be fully compliant
with the injections. The dosing frequency of q2w subcutaneous injection may not be the most practical for
patient compliance compared to less frequent dosing seen with competing injections. XolairⓇ and NucalaⓇ
may be given every 4 weeks and FasenraⓇ every 8 weeks. FasenraⓇ and NucalaⓇ are also available as
autoinjectors. XolairⓇ has pediatric indications, so patients less than 12 years old could use it.3,4,5,6,7 The most
common side effect, injection site reactions, may discourage patients use. DupixentⓇ can be administered to
a larger area compared to FasenraⓇ and NucalaⓇ, which could decrease the frequency of injection site
reactions if properly injected to different areas. Patients may be able to use DupixentⓇ therapy for the
treatment of multiple disease states. DupixentⓇ is indicated for atopic dermatitis and chronic rhinosinusitis
with nasal polyposis as well, while FasenraⓇ only has indications for asthma.

Comparator
There are currently no studies powered for direct head-to-head comparison of DupixentⓇ to anti-IL-5
monoclonal antibodies or other alternatives.8,9 Regeneron Pharmaceuticals researched the safety and efficacy
of DupixentⓇ versus other asthma therapies.10 The study focused on uncontrolled persistent asthma and
OCS-dependent asthma. In one meta-analysis, DupixentⓇ was compared to results of FasenraⓇ,
lebrikizumab, NucalaⓇ, CinqairⓇ, tralokinumab and placebo. DupixentⓇ showed the greatest increase in
FEV1 and asthma quality of life scores. It also had the second best reduction in asthma control questionnaire
scores, following NucalaⓇ.3,4,5,6,7,9

Outcome
Results in the uncontrolled persistent asthma evaluation concluded that DupixentⓇ typically has greater
outcomes for FEV1, while XolairⓇ and NucalaⓇ have not shown consistent improvements. DupixentⓇ had
better efficacy than XolairⓇ, NucalaⓇ, FasenraⓇ and CinqairⓇ in terms of NNT. DupixentⓇ 300mg was
significantly better than XolairⓇ 150 to 375 mg. There was a numerical advantage of DupixentⓇ in the
OCS-dependent trial versus NucalaⓇ and FasenraⓇ. Although DupixentⓇ had higher outcomes in terms of
FEV1 and quality of life than the alternative therapies, in the meta-analysis mentioned above there was no
statistically significant evidence that DupixentⓇ was preferred for the outcomes.9 It is important to note that
of all these therapies, only DupixentⓇ and CinqairⓇ were able to significantly lower exacerbations.
DupixentⓇ stands out from these drugs because it has the ability to block both the IL-4 and IL-13 receptors,
rather than only one IL receptor. 3,4,5,6,7,9
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Time Frame
Asthma is a chronic condition that patients will treat for most of their lives. The longest treatment period for
any clinical trial of DupixentⓇ q2w dosing lasted 52 weeks, with a 12 week follow up, seen in the Liberty
Asthma Quest.1 A year long study is not sufficient enough to determine the long term effects of DupixentⓇ,
which could potentially be a life-long drug for patients. Commonly with this class of drugs, patients can
develop antibodies, making the drug less clinically effective at the given dose. DupixentⓇ does show results
within 2 weeks, so having a year long study was able to accurately assess the short term benefits of the drug.
More extensive studies are needed in order to fully determine its efficacy and safety in long term use.1

Important Questions That Remain Unanswered
1. What is the long-term safety of DupixentⓇ post-marketing surveillance?
2. At what frequency do patients develop monoclonal antibodies to DupixentⓇ treating asthma (2%
developed neutralizing antibodies with atopic dermatitis per FDA reporting)?
3. Is there any documentation of patients becoming refractory to DupixentⓇ? If so, do the comparator drugs
still work in these patients?
4. Is this a medication that could be efficacious as maintenance therapy that is administered less frequently
than every two weeks?
5. What happens when a patient stops or is nonadherent to DupixentⓇ therapy? Can DupixentⓇ or another
competitor be resumed and still maintain efficacy?
6. Would decreasing the frequency of DupixentⓇ dosing affect the long-term safety of the therapy?
7. Does DupixentⓇ decrease overall hospitalization rates as a powered outcome variable in effectiveness
studies?
8. What is the efficacy and safety of DupixentⓇ for children with severe asthma under the age of 12?

Value and Operational Matrix
☐Substantial

⊠Modest

☐Minimal ☐
 None

How much does this product
improve over the current standard
of care?

☐Cure

Other societal considerations

DupixentⓇ allows for self-administration.

Incremental cost-effectiveness ratio
(ICER)

$351,000/ QALY

Formulary recommendation

⊠Definite include
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The medication is safe and effective for its indicated use and offers
a clinical benefit not available by any other medication on the
market.
☐Optional include
The medication is safe and effective for its indicated use, but other
clinically equivalent alternatives are available.
☐Do not include
The clinical benefits of the medication do not outweigh the cited
safety risks.
Budget Impact
Projected spend:

$31,000 (excluding the loading dose for the first year)

$ PMPM impact:

-$0.0017 PMPM
-$72.96 PMPM in year 1
-$751.09 PMPM in year 2

Utilization Management Considerations
Prior authorization recommended?

⊠ Yes

☐ Maybe

☐ No

Step therapy?

☐ 1st

☐ 2nd

Quantity limit?

Two pens per 30 days.

☐ 3rd

⊠No

Recommendations to the Committee
DupixentⓇ for subcutaneous use in moderate-to-severe asthma patients is one of few biologics currently FDA
approved for its indication, but it is the only biologic agent that targets the IL-4 pathway. This new
mechanism of action presents a new dual therapy, targeting both IL-4 and IL-13.
Compared to other biosimilars, DupixentⓇ is the only drug that can treat both atopic dermatitis and nasal
polyps, in addition to asthma. It can be administered at home, which may save patients money by avoiding
office-based physician charges. It offers the greatest convenience for the price, making it a strong contender
in the treatment of severe asthma.

Therefore, the following P&T Committee actions are recommended.
●

●

Include DupixentⓇ subcutaneous injection every 2 weeks for the treatment of
moderate-to-severe asthma with an eosinophilic phenotype or OCS-dependent asthma as a 4th
tier specialty drug on the Patient First Health Plan formulary
o preferred formulary inclusion of injection covered under the pharmacy benefits with
an approved prior authorization
FasenraⓇ, NucalaⓇ, and XolairⓇ will remain a non-preferred specialty brand requiring prior
authorization with quantity limits
8

●

●

●

●

DupixentⓇ will be preferred over other biologic therapies due to high potential cost saving in
the Patient First Health Plan medical and pharmacy benefits
o DupixentⓇ decreases medical costs due to decreased exacerbations and decreased in
office visits/injections requiring health care professional administration and
observation.
o Pharmacy benefits include medication provided by self-administration and follow-up
from Patient First Health Plan to assess adherence to therapy prior to dispensing.
Another review should be completed next year to determine any new biologics or other
therapies and changes in price. Consider any new data such as post-marketing effectiveness
and safety.
A prior authorization should be placed on DupixentⓇ before coverage is approved
o Prior authorization description on the next page
o A quantity limit of the monthly dose of DupixentⓇ should be approved
▪ 2 single-dose pens per 30 day period
▪ If higher dose or other criteria not in the prior authorization is prescribed,
prescriber must submit paperwork to support their decision with evidence.
Medical directors of Patient First Health Plan will review evidence. If
medical directors deny claim, the claim will go to external review.
o Within the prior authorization, patients must fail SoC therapy, with exceptions, to be
considered for approval
A patient adherence program should be implemented to monitor patients use to determine
further authorization and cost effectiveness for patients
o Patient must be at least 80% adherent or reauthorization should not be granted to
avoid potential loss of effectiveness
o Patients who are adherent who seem to become resistant will be tested for neutralizing
antibodies and approved for non-formulary alternatives.

Coverage Criteria: Dupixent® (dupilumab)
FDA-Approved Indication
IL-4 receptor antagonist indicated as an add-on maintenance treatment in patients with moderate-to-severe
asthma aged ≥12 years with an eosinophilic phenotype or with OCS-dependent asthma.

Criteria for Prior Authorization
DUPIXENTⓇ will be considered for coverage under the pharmacy benefit for the indication of asthma when
the following criteria are met:
- Individual is aged ≥12 years AND
-

-

Individual has a diagnosis of moderate-to-severe eosinophilic asthma as demonstrated by the
following:
- A pretreatment FEV1 less than or equal to 80% predicted AND
- FEV1 reversibility
of at least 12% and 200 mL after albuterol administration AND

One of the following:
- Individual has a blood eosinophil count (in the absence of other potential causes of
eosinophilia, including hypereosinophilic syndromes, neoplastic disease, and known or
9

-

suspected parasitic infection) greater than or equal to 300 cells/microliter at initiation of
therapy; AND
Individual has had a 3-month trial and inadequate response or intolerance to medium-to-high
dose inhaled corticosteroid
OR

-

Individual has oral corticosteroid dependent asthma; AND
Individual has had a 3-month trial and inadequate response or intolerance to high dose
inhaled corticosteroid with daily oral glucocorticoids given in combination with a controller
medication (either a LABA, or leukotriene receptor antagonist, or theophylline)
OR

-

-

Individual has an eosinophil count of less than 300 cells/microliter; AND
Individual has had 3 month trial and inadequate response or intolerance to medium-to-high
dose inhaled corticosteroid given in combination with a controller medication (either a
LABA, or leukotriene receptor antagonist, or theophylline)

Individual has experienced two or more asthma exacerbations in the prior 12 months requiring use of
systemic corticosteroid or temporary increase in the individual’s usual maintenance dosage of oral
corticosteroids.

DUPIXENTⓇ will be considered for coverage under the pharmacy benefit for the indication of atopic
dermatitis based on published studies when the following criteria are met:
- If the patient is refractory to at least 2 other medications for atopic dermatitis
DUPIXENTⓇ will be considered for coverage under the pharmacy benefit for the indication of chronic
rhinosinusitis with nasal polyposis based on FDA indication approval when the following criteria are met:
A patient has been diagnosed with chronic rhinosinusitis with nasal polyposis

Length of Initial Approval
-

12 months

Reauthorization Criteria
If the individual has experienced one or more of the following:
- Decreased use of rescue medication
- Decreased frequency of exacerbations
- Decreased yearly hospitalizations or medical care
- Increase in predicted FEV1 from the baseline before treatment
- Fewer reported symptoms related to asthma
Then patients will be eligible for reauthorization.
If patients does not demonstrate >80% medication adherence, then reauthorization will not be granted.
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Exclusions
-

Parasitic helminth infections
Pregnancy
Children under the age of 12

Clinical Evidence Evaluation

Efficacy
DupixentⓇ significantly decreased the percentage risk of an asthma-related exacerbation in the study by
Wenzel, et al., with 44% of the placebo group experiencing an exacerbation in the 12-week period while 6%
of the DupixentⓇ treated group experienced an exacerbation.10 In the study from Wenzel, et al., the
percentage change in mean of FEV1 from the baseline was 7.01% in the placebo, however in the dupilumab
treatment group, the percentage change in mean of FEV1 ranged from 14.52% to 17.34%.9 DupixentⓇ
decreased the number of employed patients with greater than one day of sick leave due to severe
exacerbation events from 11 people in the placebo group to only 5 in the DupixentⓇ treated group in a 24
week study.11 As proved in the study by Corren, the change from baseline predictions for FEV1 in the
treatment with DupixentⓇ was -0.60. In comparison to the expectations of the MCID at week 24, 76.7 out of
307 patients while only 60.1 of 158 patients exceeded in the placebo group.12 LIBERTY ASTHMA QUEST
analyzed the risk reduction percent with a 95% confidence interval in comparison to the placebo, and in
DupixentⓇ 200mg every 2 weeks, the relative risk reduction was statistically significant at 48-78%,
depending on the number of exacerbations in the previous year. In DupixentⓇ 300 mg q2w, the relative risk
reduction was statistically significant at 46-64%, also depending on the number of exacerbations in the
previous year.1
Real World Comparative Effectiveness
No comparative or effectiveness evidence is published for DupixentⓇ for asthma, however real world
evidence for atopic dermatitis has been established. Post-marketing surveillance data will help to define real
world effectiveness. Since the biologics are a high research and development expense for the manufacturers,
it is unlikely that comparison data will be published.

Safety
Safety data for the use in asthma is not widely available at this time due to DupixentⓇ’s recent approval for
the indication of asthma. Most clinical studies have not found any consistent major adverse effects. The
primary adverse effects are injection site irritation and upper respiratory tract infections; however, it is
uncommon for these adverse reactions to be severe enough for a patient to drop out of the trial.1 Because
DupixentⓇ for asthma has not been studied for its use in the real world, much of the severe safety concerns
are left unknown. In the studies observed, the largest sample size was 774 individuals who met a certain
criteria to be included in the study. Many safety observations will not be apparent until after thousands of
people are using the drug and rare adverse effects, including those that have roughly a 1 in 10,000 chance of
occurring, are being reported It is important to note that one study found that a slightly higher incidence of
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any reported adverse effect in the placebo group than the treatment group.13 The only current drug interaction
is live vaccines.14

Serious Adverse Events

Upper respiratory tract infections and bronchitis occurred in some patients while taking dupilumab.
Influenza was also noted in some participants, but there was a higher incidence of influenza in the placebo
group than the treatment groups. It has been shown that patients with elevated eosinophil levels are more
likely to have eosinophilia while on DupixentⓇ.1,13
Other Adverse Events

The most common side effect of dupilumab is injection site reactions, which occurred in approximately 9%
to 21% of participants in one study. Minor side effects included conjunctivitis, headache, and sinusitis.14

Tolerability

DupixentⓇ has been well tolerated in the treatment of asthma. Injection site reactions seem to be the largest
concern for patient adherence. One study found that patients on the 200 mg dose were significantly less
likely to discontinue therapy than the 300 mg dose, possibly due to fewer adverse effects.1

Patient Subgroups
Patients most suitable for DupixentⓇ have a blood eosinophil count of greater than or equal to 300
cells/uL, at least two exacerbations in the prior year, and an asthma control questionnaire score greater
than or equal to 1.5.2 Another subgroup that has the indication would be those that have chronis OCS use.2
Important biofactors in asthma other than blood eosinophils are FeNO, serum total IgE and eotaxin-3.
FeNO, regulated by IL-13, is a sign of epithelial inflammation. DupixentⓇ works to inhibit IL-13 and thus
lower the inflammation. This is tested by exhaling slowly into a portable device. The results are recorded
in parts per billion. One trial observed a decrease in FeNO in two weeks while taking DupixentⓇ.1 IgE, an
antibody that helps fight infection and stimulate mast cells, has also shown a gradual reduction while
taking DupixentⓇ. It can be found in a blood test. Eotaxin-3 helps regulate eosinophil migration in the
airways. It is associated with increased asthma exacerbations and a lower FEV1. The use of an
enzyme-linked immunosorbent assay.  In this trial, plasma eotaxin-3 decreased, which may be partly
responsible for fewer asthma exacerbations.

Economic Evidence Evaluation
Pharmacoeconomic data was found from the Institute for Clinical and Economic Review. There were
no other economic data found in literature comparing DupixentⓇ with other therapies. The ICER model
found DupixentⓇ to be cost effective using a budget impact model and cost-effectiveness studies, comparing
DupixentⓇ therapy to SoC and other biologics indicated for the treatment of asthma. Asthma and Allergy
Foundation of America survey found that the two most important factors for choosing a therapy for patients
with asthma included effectiveness and cost, with the former being far more important, but the cost was the
number one issue with adherence.2 Eliminating overall cost for patients will be able to increase patient
adherence and ultimately decrease the cost of treatment for the health plan. The manufacturer's dossier found
the average cost of DupixentⓇ for patients on other health plans. With insurance in place for patients, cost for
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commercial insurance members averages to $100, Medicare members are responsible for 25% of the cost,
and an average of $8 for Medicaid members. The AWP for one dose of DupixentⓇ.14 $1,811.7 for both the
200 and 300 mg doses prefilled syringes. The first year would have an additional dose cost, due to the initial
loading dose.
ICER analyzed a long term cost effectiveness study based on previous Markov models for assessing
cost-effectiveness, including ICER’s NucalaⓇ report and NICE’s XolairⓇ report. The model compared the 5
biologic therapies to reflect a lifetime horizon scenario. ICER further created and analyzed a potential budget
impact model based on US census and CDC prevalence reports. The budget impact was a 5 year model that
found DupixentⓇ to be cost-saving compared to the current treatment mix.2

Value Proposition
Summary of Product Value

Patients eligible for treatment with DupixentⓇ in Patients First Health Plan estimates to 43,000
people, calculated based on plan demographics and the US census and CDC prevalence data. Based on these
calculations and the calculations from executive summary, there was a net reduction per patient in overall
health plan costs of adding DupixentⓇ. Populations that may benefit more from DupixentⓇ therapy, including
higher eosinophil counts, ACQ scores, and greater number of exacerbations would have an effect on the net
savings as well, although are not included in the calculations or ICER analyses.
DupixentⓇ is indicated for atopic dermatitis, chronic rhinosinusitis with nasal polyposis, as well as
asthma. It is common for these conditions to be comorbid in patients, and therefore it could be possible for
DupixentⓇ to treat multiple conditions with one treatment dose. The only other two biologics with other
indications include NucalaⓇ for eosinophilic granulomatosis with polyangiitis and XolairⓇ for chronic
idiopathic urticaria. Some other societal economic considerations included cost of in office based physician
charges and the effect of patients missing work for asthma related burdens. DupixentⓇ reduces the cost of in
office based charges due to its self-administration only regimen, compared to all other biologics, which will
have some form of in office requirements. The ICER cost effectiveness studies found that there are less hours
missed per week of work for patients who are on biologics compared to the SoC. The self-administration of
DupixentⓇ presents patients with an opportunity for increased access compared to in office visits, but could
risk causing decrease in adherence. Regardless, the midwest CEPAC voting determined that
self-administration still presents as a net positive for patients. Based on evidence from manufacturing of
XolairⓇ , biologic therapies were found to reduce the average number of hours of work missed per week
compared to the SoC, potentially increasing our patients budget in order to afford the therapies.2
Incremental Cost-effectiveness

ICER estimated cost-effectiveness of DupixentⓇ compared to SoC using a Markov model. They studied
reductions in annual exacerbation rates resulting in outpatient steroid bursts, emergency department visits,
and hospitalizations. The health states followed from start of treatment until death included asthma
non-exacerbation state (day to day symptoms), asthma exacerbation state, and death. Baseline characteristics
were averaged to eliminate difference that would affect outcomes of cost. The long-term cost effectiveness
model compared the 5 biologic treatment options based on QALY and annual prices from manufacturers.
DupixentⓇ’s cost effectiveness ratio was $351,000/QALY and annual price of $31,000. The ratio was near
the average of the biologics, with XolairⓇ being lowest at $325,000/QALY and reslizumab being highest at
$391,000/QALY. The annual price of DupixentⓇ was highest, compared to benralizumab at the lowest of
$27,800 per year. The model assumed that costs and outcomes to be discounted to 3% per year. Limitations
to this model were based around lack of evidence involving long-term studies on treatment or discontinuation
rate and lack of evidence for subpopulations.1
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Summary of incremental cost-effectiveness ratios found by studies included in this review.

Base-case incremental cost effectiveness ratio for DupixentⓇ is $351,000/QALY.

Budget Impact
ICER used a five-year model, based on the cost-effectiveness, to estimate costs and impact of DupixentⓇ
displacing other biologics from the market. The model estimated the potential population eligible for
DupixentⓇ use (237,000 patients per year) by using population data. The estimates were based on the US
consensus and CDC prevalence data of asthma. The model compared DupixentⓇ therapy to the current
treatment mix, which consists of 27% biologic therapy and 73% SoC. Current market share estimates among
biologic therapies for the treatment of asthma include 1.8% reslizumab, 5.2% benralizumab, 18.2%
mepolizumab, and 74.9% omalizumab. XolairⓇ is the main competitor for DupixentⓇ in the budget impact
model. Based on an annual WAC, DupixentⓇ costed about $1,400 more than the current treatment mix.
Annual net price resulting in per patient savings of about $5,700 and all cost effective QALY thresholds
resulted in cost savings ranging from $22,000 to $31,000.1
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Clinical Evidence Tables

Reference: Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, et al. Dupilumab efficacy and safety in
adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a
long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet
Respir Med. 2016 Jul 2;388(10039):31–44.
Study
Design
and
Evidence
Grade

Phase IIb
DB/PC

Drug Regimens

- Placebo

N

776

- DupixentⓇ, 200 mg
- DupixentⓇ,300 mg
(all SUBQ)

Endpoints

Time
Horizo
n
24
weeks
2
weeks/4
weeks

Study Population

Adults 18 years of age
or older with
- Asthma diagnosis for
the past 12 months or
more
- Medium-to-high dose
inhaled corticosteroid
treatment and
long-acting B2 agonist
at least 1 month before
screening
- FEV1 of 40-80%
- 5-item Asthma Control
Questionnaire score of
1-5 or higher
- Reversibility of at least
12% and 200 mL

Primary

Secondary

FEV1 compared in patients with
baseline blood eosinophil counts of
at least 300 eosinophils per
microliters.

Efficacy/Effectiveness

Eosinophil count of at least
300 eosinophils per
microliter

Serious Adverse Events

Dupilumab vs. Placebo in overall population (n=776)
Placebo

Dupiluma
b, 200
mg/4
weeks

Dupiluma
b,
300 mg/4
weeks

Dupiluma
b, 200
mg/2
weeks

Dupiluma
b, 300
mg/4
weeks

N (%)

n=158

n=154

n-157

n=150

n=157

Greater
than 1
exacerbati
on in the
24 week
period

41 (26)

23 (15)

28 (18)

13 (9)

17 (11)

LS mean
change in
FEV1
from
baseline at
week 24
(%)

7.01

14.52

Risk
reduction
vs.
placebo
(%)

-

P value vs.
placebo

-

53.7

15.68

33.2

16.62

70.0

17.34

Dupilumab
Regimens

PBO

N (%)

n=611

n=158

AE leading to
discontinuation

27 (4)

5 (3)

Upper respiratory
infection

83 (14)

28 (18)

Injection site
reaction

79 (13)

12 (8)

Headache

62 (10)

20 (13)

Nasopharyngitis

59 (10)

15 (9)

Bronchitis

51 (8)

16 (10)

Influenza

38 (6)

5 (3)

Sinusitis

36 (6)

11 (7)

70.5

Weaknesses Impacting Internal/External Validity
0.0093

0.1380

0.0002

0.0001
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● Short duration of the study in patients with uncontrolled
persistent asthma
● Small number of patients per dose regimen
● Study not powered to directly compare the different dosing
levels of dupilumab
● Approved treatment options remain limited

Reference: Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, et al. Dupilumab in Persistent Asthma
with Elevated Eosinophil Levels. New England Journal of Medicine. 2013;368(26):2455–66.
Study
Design
and
Evidence
Grade

Phase 2A
PC, PG, DB,
RCT

Drug Regimens

- Placebo
- Dupilumab, 300mg
(SUBQ)
- Fluticasone, 250 or 500
ug
- Salmeterol, 50 ug

N

104

Endpoints

Time
Horizo
n
12
weeks

Study Population

Primary

Secondary

- 18-65 years of age
- Occurence of an asthma
- Moderate to severe
exacerbation
asthma
- Blood eosinophil count
of at least 300 cells per
microliter
- Sputum eosinophil
level of at least 3%
- Medium to high dose
inhaled glucocorticoids
usage
- Long acting beta
agonist usage

Efficacy/Effectiveness

- Occurence of an asthma
exacerbation
- Estimate for asthma
exacerbation
- Change in FEV1 baseline
- Change in morning PEF
- Change in evening PEF
- Change in ACQ5 score
- Morning asthma symptom
score
- Evening asthma-symptom
score
- Number of nocturnal
awakenings
- SNOT-22 score
- Number of inhalations of
albuterol or levalbuterol in
24 hour period

Serious Adverse Events

Placebo

Dupilumab

N (%)

n=52

n=52

Occurence of
exacerbation during
12-week intervention
period

23 (44)

3 (6)

Greater than 30%
reduction in morning
PEF from baseline on 2
consecutive days

10 (19)

Greater than 6
inhalations of albuterol
or levalbuterol in a
24-hour period relative to
baseline on 2 consecutive
days

10 (19)

Kaplan-Meier estimate
for probability of asthma
exacerbation at 12 weeks
(95% CI)

0.46 (0.32 to 0.60)

Change in FEV1,
baseline to week 12

-0.22 +/- 0.06

1 (2)

1 (2)

0.06 (0.00 to 0.12)

0.05 +/- 0.06

Placebo

Dupilumab

N (%)

N=52

N=52

Any adverse
event

40 (77)

42 (81)

Any serious
adverse event

3 (6)

1 (2)

Study
discontinuation
owing to adverse
event

3 (6)

3 (6)

Death

0

0

Injection site
reactions

5 (10)

15 (29)

Nasopharyngitis

2 (4)

7 (13)

Upper respiratory
tract infection

9 (17)

7 (13)

Headache

3 (6)

6 (12)

16

(liters)

Nausea

1 (2)

4 (8)

Arthropod bite

0

3 (6)

Muscle spasms

0

3 (6)

Nasal congestion

1 (2)

3 (6)

Rash

1 (2)

3 (6)

Viral upper
respiratory tract
infection

0

3 (6)

Sinusitis

5 (10)

1 (2)

Gastroenteritis
(viral)

3 (6)

0

Rhinitis, seasonal

3 (6)

0

Weaknesses Impacting Internal/External Validity
●

Short duration of the study in patients with
uncontrolled persistent asthma

●

Small number of patients per dose regimen

Reference: Corren JN, Castro MM, Chanez Pundefined, Fabbri Lundefined, Joish Vundefined, Amin Nundefined, et
al. Dupilumab improves symptoms, quality of life, and productivity in uncontrolled persistent asthma. Eur Ann
Allergy Clin Immunol. 2019;122(1):41–9.
Study
Design
and
Evidence
Grade
Phase IIb
Dose
ranging,
RCT, DB,
PC, PG

Drug Regimens

-200 mg Dupilumab
- 300 mg Dupilumab
(Both SUBQ)

N

465

Time
Horizo
n
24
weeks

Endpoints

Study Population

- Adults with asthma
diagnosis for 12 months
or longer
- Treatment with
medium to high dose
ICS+LABA with a
stable dose for 1 month
or longer before
screening
- FEV 40-80% of
predicted with
reversibility of at least
12%
- 5-item ACQ-5 score of
1.5 or higher at baseline

Efficacy/Effectiveness

N (%)

Primary
- Eosinophil count less than 300
and at least 300 cells per microliter

Secondary
- Eosinophil count less than
300 and at least 300 cells
per microliter
- Changes from baseline at
week 24 for ACQ-5, AM
and PM asthma scores, and
AQLQ total scores

Serious Adverse Events

Placebo

Dupilumab, 200
mg/2 weeks

Dupilumab, 300
mg/2 weeks

n=158

n=150

n=157

● Injection site reaction
o
20% Dupilumab 200
o
26% Dupilumab 300
o
13% Placebo
Weaknesses Impacting Internal/External Validity

17

20

●

Total number of
severe
exacerbation
events

75

23

Number of
employed patients
with greater than
one day of sick
leave due to
severe
exacerbation
event

11 (11.8)

4 (4.9)

5 (5.7)

Proportion of
patients meeting
or exceeding the
MCID (ACQ-5
total score)

60.1

76.7

72.6

●

Short duration of the study in patients with
uncontrolled persistent asthma
Small number of patients per dose regimen

Reference: Dupixent. Sanofi and Regeneron Pharmaceuticals, Inc. edossier AMCP P&T
Competition.https://www.amcpfoundation.org/student-pharmacists/amcp-foundation-annual-pt-competition/20
20-p-t-competition. 2019.
Study
Design
and
Evidence
Grade
IIB, pivotal
RCT, DB,
PC,
dose-rangin
g

Drug Regimens

- Dupilumab, 200 mg/4
weeks
- Dupilumab, 300 mg/4
weeks
- Dupilumab, 200 mg/2
weeks
- Dupilumab, 300 mg/2
weeks
(all SUBQ)

N

776

Time
Horizo
n
40
weeks

Endpoints
Study Population

- Patients 18 years of
age or older with asthma
diagnosis for 12 months
or more
- Current treatment with
medium-to-high dose
ICSs plus a LABA with
a stable dose for one
month or greater before
screening
- Pre-baseline FEV1 of
40% to 80%,
reversibility of 12% or
greater
- 200 mL in FEV1 after
the administration 200
ug to 400 ug salbutamol
at screening
- ACQ-5 score at or
greater than 1.5 at
screening and baseline
visit

Primary

Secondary

- Greater than 1 severe exacerbation
in the 24-week treatment period
- Adjusted AER
- Change in FEV1 from baseline to
Week 12, L, LS mean (SE)
- Change in Fev1 from baseline to
Week 24, L, LS mean (SE)
- Change in FEV1 from baseline to
Week 24, L, LS mean (SE)

- Change in ACQ-5 score
from baseline to Week 24, S
mean (SE)
- Change in AQLQ score
from baseline to week 24,
LS mean (SE)
- Change in AM asthma
symptom score from
baseline to week 24
- Change in PM asthma
symptom score from
baseline to week 24, LS
mean (SE)
- Change in FeNO form
baseline to Week 24, LS
mean (SE)

Efficacy/Effectiveness

Placebo

Serious Adverse Events

Dupixent

Dupixent

Dupixent

Dupixent

Ⓡ

200mg
q4w

Ⓡ

, 300mg
q4w

Ⓡ

, 200mg
q2w

Ⓡ

, 300mg
q2w

N (%)

N=158

N=154

N=157

N=150

N=157

Change in
ACQ-5

-1.14
(0.08)

-1.32
(0.08)

-1.34
(0.08)

-1.49
(0.08)

-1/45
(0.08)

Patients with,
n (%)

Placebo

Combined
DupixentⓇ

N=158

N=611

Any TEAE

18 (75)

483 (79)

Any

9 (6)

45 (7)
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score from
baseline

treatment-eme
rgent SAE

Change in
AQLQ
score from
baseline

0.88
(0.09)

1.12
(0.09)

1.18
(0.08)

1.20
(0.09)

1.24
(0.08)

Change in
AM
asthma
symptom
score from
baseline to
Week 24

-0.36
(0.05)

-0.53)
(0.05)

-0.54
(0.05)

-0.57
(0.05)

-0.56
(0.05)

Change in
PM
asthma
symptom
score from
baseline to
week 24

-0.39
(0.06)

-0.52
(0.06)

-0.59
(0.06)

-0.60
(0.06)

-0.61
(0.06)

Change in
FeNO
from
baseline to
Week 24

10.91
(5.39)

-5.47
(5.75)

-16.61
(5.55)

-21/86
(5.59)

-29.39
(5.44)

Any TEAE
leading to
treatment
discontinuatio
n

5 (3)

27 (4)

Any TEAE
leading to
death

0

2 (less than 1)

URTI (greater
than 5% of
patients)

28 (18)

83 (14)

Injection site
erythema
(greater than
5% of
patients)

12 (8)

79 (13)

Headache

20 (13)

62 (10)

Nasopharyngit
is

15 (9)

59 (10)

Bronchitis

16 (10)

51 (8)

Influenza

5 (3)

38 (6)

Sinusitis

11 (7)

36 (6)

URTI (greater
than 10% of
patients)

56 (35)

216 (35)

Injection site
reaction
(greater than
10% of
patients)

21 (13)

110 (18)

Bacterial
infections

3 (2)

5 (1)

Herpes viral
infections

1 (1)

3 (less than 1)

Weaknesses Impacting Internal/External Validity
●

Short duration of the study in patients with
uncontrolled persistent asthma

●

Small number of patients per dose regimen

●

Only q2w dosing was evaluated into Phase III

●

Approved treatment options remain limited
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Reference: Rathinam KK, Abraham JJ, Vijayakumar TM. Dupilumab in the Treatment of Moderate to Severe
Asthma: An Evidence-Based Review. Curr Ther Res Clin Exp. 2019 Oct 15;91:45–51.
Study
Design
and
Evidence
Grade

Drug Regimens

N

Time
Horizo
n

Endpoints

Databases searched

Primary

Secondary

PubMed
Cochrane library
Embase
ClinicalTrials.gov

MA,
Systematic
search
Efficacy/Effectiveness

Serious Adverse Events

Efficacy and safety profile of dupilumab in the treatment of moderate-to-severe
asthma
Addition of dupilumab to conventional therapy improves FEV1 and reduces risk of
severe asthma exacerbations in patients.
Using dupilumab with LABAs used with inhaled corticosteroids improves clinical
outcomes and quality of life in patients with moderate to severe asthma.

Weaknesses Impacting Internal/External Validity
● Still in emerging stage of acceptance
● Ongoing studies needed to determine dupilumab’s long-term
efficacy and safety for future extensive use

Abbreviations used in this table: AC =active control, CCS = case-control study, DB = double blind, PC = placebo control, PCS =
prospective cohort study, PG = parallel group, MA = meta-analysis MC = multicenter, RCS = retrospective cohort study, RCT =
randomized controlled trial, XO = crossover.
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Cost-Effectiveness Evidence Summary

Ref. and
Sponsor

1. Budget Impact
Model (BIM) of

QHES
Score

100

DupixentⓇ
against Current
Treatment Mix

Study Design
and
Treatments
Compared

Time Horizon
and
Demographics

ICER model using
the potential
population for

Time: 5 year
analysis

DupixentⓇ
(approximately
237,000 patients
per year)

Demographics:
1.2 million patients
over 5 years or
approximately
237,000 per year
with moderate to
severe asthma

Comparing
DupixentⓇ to
current treatment
mix (27% on
biologics and 73%
on SoC)

Model Inputs
and Data
Sources

Results:
Base Case, Sensitivity Analysis and Limitations

- Population data
Base Case: Per Patient Budget Impact Calculation Over 5 Years
from census and
CDC prevalence
Average Annual Per Patient Budget Impact
data in 2016
- Market share
WAC
Net Price
$150,000/
$100,000/
$50,000/Q
based on IQVIA
QALY
QALY
ALY
US Defined Daily
Doses for July 2018
Dupilumab
$46,059
$38,912
$22,127
$17,945
$13,764
- 2017 National
Population
Current
$44,651
Treatment
Projections Datasets
Mix
- Treatment costs
Difference
(Dupilumab
- Current
Treatment
Mix)

Biggest competitor

$1,408

($5,738)

($22,524)

($26,705)

($30,887)

of DupixentⓇ is
XolairⓇ (74.9% of
biologics)

Sensitivity Analysis: One-way sensitivity analysis on current and future
drug prices.
Limitations: Refer to the Markov model below (#2), which was the
same model used to determine cost-effectiveness analysis.

2. Long-Term
Cost
Effectiveness

100

Markov model
based on models
formerly
developed for
Ⓡ

Xolair

and

NucalaⓇ
Comparing 5
biologic therapies
for lifetime
cost-effectiveness
based on QALY

Time: Lifelong
horizon
Demographics:
Mean age = 46,
62% female, 17%
chronic OCS users

- Average life
expectancy
- NICE reports
- FDA labeled
population
- Manufacturer net
price data

Base Case: Incremental Cost-Effectiveness Ratio and Annual Price
Incremental
Cost-Effectiveness
Ratio

Annual Price

Omalizumab

$325,000

$28,900

Mepolizumab

$344,000

$29,500

Reslizumab

$391,000

$28,900

Benralizumab

$371,000

$27,800

Dupilumab

$351,000

$31,000

Sensitivity Analysis: One-way sensitivity analysis. Given Willingness
to pay, non-exacerbation utility improvement, exacerbation reductions,
and chronic oral steroid reduction.
Limitations: No long run clinical evidence on biologic treatment
responders or discontinuation rate, further research is suggested. Lack
of clinical evidence for subpopulations with income or ethnic
disparities

Abbreviations used in this table: LYS = life-years saved, QALY = quality-adjusted life-year, QOL = quality of life.
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Background

Disease Background
Chronic inflammation of the airway, unregulated expiratory airflow and a multitude of symptoms, such as
shortness of breath and coughing, are just a few of the characteristics that often accompany asthma. It is
estimated that asthma affects 23 million Americans. In adolescence, there are higher rates of the disease
in males, but an alteration occurs into adulthood where females have a higher prevalence. 11.6% of those
with asthma are African American, followed by 8.3 % of white non-hispanics. Risk factors include
genetics, weight, sex, allergans and air pollution, among others.1

Disease Burden

On average, the US economy spends nearly $80 million annually on asthma according to a study
conducted from 2008-2013. The study projected that more than 15 million Americans had asthma. More
recent estimates are up to 23 million affected by the disease, which would increase this economic
projection. The social aspects of the disease are taxing. Symptoms can be difficult to control, and
exacerbations can get in the way of daily tasks, such as work or school, leading to a diminished quality of
life. Sleeping through the night can also prove difficult. Asthma can deter adolescents from playing sports
even though oftentimes exercise can help with symptoms. In some cases, having asthma can prevent one
from joining the military. Traveling to places with high altitudes or humidity can make breathing
difficult.15
Pathophysiology

Type 2 inflammation occurs due to a specific type of CD4+ T-cells (Th2). Typically, type-2 asthma is
triggered by allergens, bacteria and viruses. When an allergan comes into contact with a dendritic cell, it
differentiates into a Th2 cell through the aid of IL-4. This newly formed Th2 cell, in turn, then stimulates
the release of more IL-4, IL-5 and IL-13. These three IL are called type2-associated cytokines because
they drive the inflammatory response. IL-4 triggers B-cells to make IgE, which causes mast cells to
secrete inflammatory mediators such as histamine, and recruit eosinophils to sites of tissue injury. IL-13
has the same capabilities as IL-4, in addition to mucus production, smooth muscle contractility and
collagen deposition. IL-5 primarily acts on eosinophil migration and maturation.17,18 Through all of these
changes, the airway tries to compensate through bronchoconstriction and mucus plugging of the inflamed
airway.1

Treatment Alternatives
There are pharmacologic options for the treatment of asthma in multiple dosage forms. Inhaled
medications are often more advantageous because they can go directly to the lungs at higher
concentrations. Many devices for this type of drug delivery exist. Nonpharmacologic treatments include
finding triggers and avoiding them when possible.16

Preferred Existing Therapy

Inhaled corticosteroids are the most effective treatment for asthma. This drug class suppress cytokines and
inflammatory mediators. When the use of an inhaled corticosteroid is not enough to control asthma, the
22

addition of a LABA or omalizumab may be necessary to improve lung function. LABAs are not
recommended for monotherapy because they cannot control exacerbations.16

Other Therapeutic Alternatives

Oral systemic corticosteroids may be used if the asthma is difficult to control or severe. There is some
hesitation in this being first-line therapy due to a large number of side effects possible. Immunotherapy is
an option for those that have ineffective medication therapy and suffer from symptoms all year round.
Cromolyn sodium is another alternative treatment used before exercise or exposure to a known trigger.
Leukotriene modifiers are an adjunct therapy to LABA, but only show modest improvement.16

Product Background
Pharmacology

DupixentⓇ is a human monoclonal IgG4 antibody that inhibits the IL-4 and IL-13 signaling mechanism.
In doing so, proinflammatory cytokines and IgE cannot be released. It accomplishes this by binding to the
IL-4Rα subunit.14
Pharmacokinetics12

Route of administration

Subcutaneous injection

Bioavailability

61% to 64%

Time to peak

Approximately 1 week

Plasma half-life

There is limited human data on half-life

Route(s) of elimination

Monoclonal antibodies do not undergo significant renal elimination. It
is possible that DupixentⓇ is eliminated in two ways. It is hypothesized
that at high concentrations, a proteolytic pathway is used. At low
concentrations, saturable and a non-linear pathway is used.

Methodology
DupixentⓇ compared to IL-5 antibodies as maintenance add-on treatment for moderate-to-severe asthma
with eosinophilic phenotype or OCS dependent asthma from 2017.

Databases Searched
Academic Search Complete including PubMed, Medline, International Pharmaceutical Abstracts,
CINAHL, ProQuest
Secondary Sources
Icer-Review.org
Lexicomp
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Search Strategy
DupixentⓇ, dupilumab, asthma, monoclonal antibodies, eosinophilic asthma

Inclusion Criteria

RCT, Meta-analyses, systematic reviews, control intervention studies
Search Results

Study Type
Randomized controlled trials (RCT)
Meta-analyses of RCTs
Systematic reviews
Cost-utility modeling studies
Budget impact modeling studies
Control intervention studies
Other (not peer-reviewed)

N
34
5
7
1
1
6
1

Published
X
X
X
X
X
X
X

Unpublished

Articles Excluded from Evidence Synthesis

Reason for Exclusion
Study was not randomized

N
1
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